
Rebecca A Harrison

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5119411/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Post Stroke Pain: Identification, Assessment, and Therapy. Cerebrovascular Diseases, 2015, 39, 190-201.	1.7	290
2	SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro-Oncology, 2021, 23, 1835-1844.	1.2	64
3	Measuring Self-Reported Cancer-Related Cognitive Impairment: Recommendations From the Cancer Neuroscience Initiative Working Group. Journal of the National Cancer Institute, 2021, 113, 1625-1633.	6.3	46
4	Ventral hippocampal involvement in temporal order, but not recognition, memory for spatial information. Hippocampus, 2008, 18, 251-257.	1.9	37
5	A Naturalistic Study of Predictors and Risks of Atypical Antipsychotic Use in an Attention-Deficit/Hyperactivity Disorder Clinic. Journal of Child and Adolescent Psychopharmacology, 2009, 19, 575-582.	1.3	33
6	Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. Clinical Cancer Research, 2020, 26, 3565-3577.	7.0	30
7	A Narrative Review of Persistent Postâ€Stroke Headache – A New Entry in the International Classification of Headache Disorders, 3rd Edition. Headache, 2018, 58, 1442-1453.	3.9	24
8	Cortical Brain Age from Pre-treatment to Post-chemotherapy in Patients with Breast Cancer. Neurotoxicity Research, 2020, 37, 788-799.	2.7	22
9	Overlapping autoimmune syndrome: A case of concomitant anti-NMDAR encephalitis and myelin oligodendrocyte glycoprotein (MOG) antibody disease. Journal of Neuroimmunology, 2020, 339, 577124.	2.3	21
10	Intracranial dural, calvarial, and skull base metastases. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 149, 205-225.	1.8	20
11	Nitrous Oxide (N ₂ O)-Induced Acute Psychosis. Canadian Journal of Neurological Sciences, 2014, 41, 672-674.	0.5	17
12	Neurologic Toxicities of Cancer Immunotherapies: a Review. Current Neurology and Neuroscience Reports, 2020, 20, 27.	4.2	17
13	Neurocognitive Function in Adult Cancer Patients. Neurologic Clinics, 2018, 36, 653-674.	1.8	15
14	Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center. European Journal of Cancer, 2019, 112, 83-93.	2.8	15
15	Functional connectome biotypes of chemotherapy-related cognitive impairment. Journal of Cancer Survivorship, 2020, 14, 483-493.	2.9	15
16	A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. CNS Oncology, 2022, 11, CNS87.	3.0	15
17	Pre-surgical connectome features predict IDH status in diffuse gliomas. Oncotarget, 2019, 10, 6484-6493.	1.8	14
18	Neurocognitive dysfunction in adult cerebellar medulloblastoma. Psycho-Oncology, 2019, 28, 131-138.	2.3	12

REBECCA A HARRISON

#	Article	IF	CITATIONS
19	Treatment of Glioblastoma in the Elderly. Drugs and Aging, 2018, 35, 707-718.	2.7	11
20	Neurocognitive Impairment After Hematopoietic Stem Cell Transplant for Hematologic Malignancies: Phenotype and Mechanisms. Oncologist, 2021, 26, e2021-e2033.	3.7	11
21	Predicting Patient Reported Outcomes of Cognitive Function Using Connectome-Based Predictive Modeling in Breast Cancer. Brain Topography, 2020, 33, 135-142.	1.8	10
22	Aggressiveness of care at end of life in patients with highâ€grade glioma. Cancer Medicine, 2021, 10, 8387-8394.	2.8	9
23	The association of genetic polymorphisms with neuroconnectivity in breast cancer patients. Scientific Reports, 2021, 11, 6169.	3.3	8
24	Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma Journal of Clinical Oncology, 2020, 38, 3615-3615.	1.6	8
25	Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM) Journal of Clinical Oncology, 2020, 38, 2511-2511.	1.6	7
26	Cell Signaling Pathways in Brain Tumors. Topics in Magnetic Resonance Imaging, 2017, 26, 15-26.	1.2	5
27	Pearls & Oy-sters: Primary Pineal Melanoma With Leptomeningeal Carcinomatosis. Neurology, 2021, 97, 248-250.	1.1	4
28	A phase I/II clinical trial of autologous CMV-specific T cells in glioblastoma (GBM) patients to reveal a lack of immune effector function Journal of Clinical Oncology, 2020, 38, 2515-2515.	1.6	2
29	Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma Journal of Clinical Oncology, 2020, 38, 3617-3617.	1.6	2
30	Neurologic Toxicities of Immunotherapy. Advances in Experimental Medicine and Biology, 2021, 1342, 417-429.	1.6	2
31	RARE-63. MULTICENTRIC GLIOMA IN OLLIER DISEASE: AÂCASE REPORT AND REVIEW OF THE LITERATURE. Neuro-Oncology, 2016, 18, vi172-vi172.	1.2	1
32	NCOC-17. EVALUATION OF NEUROCOGNITIVE FUNCTION IN PATIENTS WITH CEREBELLAR MEDULLOBLASTOMA. Neuro-Oncology, 2016, 18, vi123-vi123.	1.2	0
33	Patterns of care for pediatric patients with newly-diagnosed grade II gliomas. Child's Nervous System, 2021, 37, 1563-1572.	1.1	0
34	A phase 1/2 study of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma Journal of Clinical Oncology, 2021, 39, TPS2071-TPS2071.	1.6	0
35	First Case of Association between Autoimmune Autonomic Ganglionopathy (AAG) and Myeloproliferative Neoplasms (MPNs). Blood, 2021, 138, 4629-4629.	1.4	0